Cyient's profit fell 31.7 per cent quarter-on-quarter (Q-o-Q) to Rs 122.3 crore in Q3FY25, from 179.1 crore in the September ...

Dr Reddy’s shares tumbled up to 6% in early trade and at 9:46 am, they were trading 4.35% lower at Rs 1,233.25 on the Bombay Stock Exchange (BSE).

Spandana Sphoorty Financial fell 5 per cent to Rs 324.65. The stock has lost 54 per cent of its market value in the past six months and 70 per cent in the past one year.

RBI conducts VRR auctions to ease liquidity tightness in banking system, with system liquidity deficit widening.

Dr. Reddy's Laboratories shares fell by 6.2% after the company reported a marginal 2% YoY growth in Q3 FY25 net profit to Rs 1,413 crore. Despite robust revenue growth, Jefferies, Nuvama, and DAM ...

Infra.Market: The round witnessed participation from several prominent investors, including Tiger Global, Evolvence, Foundamental GmbH, Ashish Kacholia, Nikhil Kamath, Abhijit Pai, Sumeet Kanwar, ...

Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...

Nuvama slashed its FY25 and 26 EPS estimates by 10.8 per cent and 4.5 per cent, respectively, on lower growth and margins. It suggested a revised target price of Rs 1,660 from Rs 1,700 earlier.

Goldman Sachs reportedly has maintained a 'Buy' rating and increased its target price to Rs 12,580, up from Rs 12,460, citing volume recovery and lower costs contributing to margin improvement ...

IndiGo’s net profit is expected to fall 34% to ₹1,974 crore in Q3FY25 from ₹2,998.1 crore YoY. The company posted a net loss of ₹986.7 crore in the previous quarter.

Companies like Bank of India, Aditya Birla Money, Centrum Capital, DCB Bank, EMS Ltd, Granules India, Trident, Ugro Capital, ...

The company has partnered with Kotak Mahindra Capital, IIFL Capital, Goldman Sachs, Jefferies, ICICI Securities, HSBC Securities, Motilal Oswal Financial Services, and Nuvama Wealth Management, to ...